Literature DB >> 23469974

Circulating miRNAs as new blood-based biomarkers for solid cancers.

Martina Redova1, Jiri Sana, Ondrej Slaby.   

Abstract

miRNAs are short noncoding RNAs that post-transcriptionally regulate gene expression. miRNAs' ability to inhibit translation of oncogenes and tumor suppressor genes implies they have an involvement in carcinogenesis. Specific miRNA expression signatures have been identified in a variety of human cancers. More recently, occurrence of miRNAs in the blood serum and plasma of humans has been repeatedly observed. miRNA levels in serum and plasma are more stable, reproducible and consistent among individuals of the same species in comparison with other circulating nucleic acids. Circulating miRNAs have been successfully evaluated in a wide range of solid cancers as promising novel noninvasive biomarkers of early disease onset or relapse. Here we describe the origin of circulating miRNAs, principles of their immense stability and proposed functions, and comprehensively summarize studies focusing on their significance in the most frequently studied cancer types in this regard, including breast, colorectal, lung and prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23469974     DOI: 10.2217/fon.12.192

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  42 in total

Review 1.  The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma.

Authors:  Muhammad Nauman Aftab; Marcel E Dinger; Ranjan J Perera
Journal:  Arch Biochem Biophys       Date:  2014-07-24       Impact factor: 4.013

2.  Clinical evaluation of 4 types of microRNA in serum as biomarkers of esophageal squamous cell carcinoma.

Authors:  Kai Wang; Dongmei Chen; Yue Meng; Jianjun Xu; Qingyun Zhang
Journal:  Oncol Lett       Date:  2018-05-16       Impact factor: 2.967

3.  Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma.

Authors:  Feng Zhi; Naiyuan Shao; Rong Wang; Danni Deng; Lian Xue; Qiang Wang; Yi Zhang; Yimin Shi; Xiwei Xia; Suinuan Wang; Qing Lan; Yilin Yang
Journal:  Neuro Oncol       Date:  2014-08-18       Impact factor: 12.300

4.  mRNAs and miRNAs in whole blood associated with lung hyperplasia, fibrosis, and bronchiolo-alveolar adenoma and adenocarcinoma after multi-walled carbon nanotube inhalation exposure in mice.

Authors:  Brandi N Snyder-Talkington; Chunlin Dong; Linda M Sargent; Dale W Porter; Lauren M Staska; Ann F Hubbs; Rebecca Raese; Walter McKinney; Bean T Chen; Lori Battelli; David T Lowry; Steven H Reynolds; Vincent Castranova; Yong Qian; Nancy L Guo
Journal:  J Appl Toxicol       Date:  2015-04-29       Impact factor: 3.446

Review 5.  Diagnostic, prognostic and therapeutic potential of long noncoding RNAs in cancer.

Authors:  Muhammad Babar Khawar; Syeda Eisha Hamid; Tayyba Jan; Muddasir Hassan Abbasi; Muhammad Idnan; Nadeem Sheikh
Journal:  Mol Biol Rep       Date:  2022-01-24       Impact factor: 2.316

6.  MicroRNA-17 family as novel biomarkers for cancer diagnosis: a meta-analysis based on 19 articles.

Authors:  Ronghe Gu; Shiqing Huang; Weiguo Huang; Yuming Li; Huijiang Liu; Lijing Yang; Zhonggui Huang
Journal:  Tumour Biol       Date:  2015-12-02

7.  Clinical significance of urothelial carcinoma associated 1 in colon cancer.

Authors:  Kun Tao; Jing Yang; Yuemei Hu; Yaohua Sun; Zhenyu Tan; Jinglin Duan; Feng Zhang; Hongli Yan; Anmei Deng
Journal:  Int J Clin Exp Med       Date:  2015-11-15

8.  miRNA profiling in serum and tissue samples to assess noninvasive biomarkers for NSCLC clinical outcome.

Authors:  D Petriella; S De Summa; R Lacalamita; D Galetta; A Catino; A F Logroscino; O Palumbo; M Carella; F A Zito; G Simone; S Tommasi
Journal:  Tumour Biol       Date:  2015-11-13

9.  Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma.

Authors:  N-s Lai; D-g Wu; X-g Fang; Y-c Lin; S-s Chen; Z-b Li; S-s Xu
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

10.  Serum miR-210 Contributes to Tumor Detection, Stage Prediction and Dynamic Surveillance in Patients with Bladder Cancer.

Authors:  Yongmei Yang; Ailin Qu; Jingkang Liu; Rui Wang; Yingjie Liu; Gang Li; Weili Duan; Qian Fang; Xiumei Jiang; Lili Wang; Guixi Zheng; Lutao Du; Xin Zhang; Chuanxin Wang
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.